Blog
RSS FeedPosted by Michael Wonder on 13 Apr 2023
Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement
11 April 2023 - The aims of this study were to review the current interactions within and across regulatory and HTA ...
Posted by Michael Wonder on 07 Feb 2023
The EU butts heads with big pharma to make medicines cheaper
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 23 Jul 2022
European Union regulation of health technology assessment: what is required for it to succeed?
22 July 2022 - After considerable discussion and debate, the European Commission proposal for the regulation of health technology assessment was ...
Posted by Michael Wonder on 09 Feb 2022
Topic selection process in health technology assessment agencies around the world: a systematic review
7 February 2022 - The purpose of this study was to systematically review the process for topic selection by health technology ...
Posted by Michael Wonder on 02 Feb 2022
Understanding innovation of health technology assessment methods: the IHTAM framework
31 January 2022 - Adequate methods are urgently needed to guarantee the good practice of health technology assessment for technologies with ...
Posted by Michael Wonder on 02 Nov 2021
Pricing vaccines and drugs in Europe: worth differentiating?
1 November 2021 - The COVID-19 pandemic has recently brought to the forefront the vital importance of vaccines, of which Europe ...
Posted by Michael Wonder on 20 Oct 2021
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
20 October 2021 - Medical devices are potentially good candidates for coverage with evidence development schemes, as clinical data at market ...
Posted by Michael Wonder on 28 Apr 2021
Do existing real world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
28 April 2021 - Technological and computational advancements offer new tools for the collection and analysis of real world data. ...
Posted by Michael Wonder on 20 Jan 2021
Patient involvement in relative effectiveness assessments in the European Network for Health Technology Assessment
20 January 2021 - Patient involvement in the process of producing health technology assessments has become increasingly important. In the ...
Posted by Michael Wonder on 23 Oct 2020
Efficiency ratio and rocketing drug prices: old concerns and new possibilities
23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...
Posted by Michael Wonder on 18 Oct 2020
Community engagement in health technology assessment and beyond: from guests in the process to hosts
15 October 2020 - In health technology assessment, clinical and economic evidence are assessed in the regulatory and reimbursement environments, with ...
Posted by Michael Wonder on 05 Sep 2020
Real world evidence to support payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders
3 September 2020 - There are divergent views on the potential of real world data to inform decisions made by regulators, ...
Posted by Michael Wonder on 15 Jul 2020
The impact of managed entry agreements on pharmaceutical prices
6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...